Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-436 | Luminespib | HSP90 | Misc | 0.0039107 | -0.0492 | 0.6326 | 0.0393 | 3.6046 | 0.004027 | 0.999 |
MDA-MB-436 | A-1210477 | Mcl-1 | Misc | Inf | 0.8728 | 0.0140 | 0.0010 | 0.0000 | Inf | 0.42977 |
MDA-MB-436 | Olaparib | PARP | Misc | 1.536 | 0.2383 | 0.3050 | 0.0296 | 0.3132 | 51.2767 | 0.98251 |
MDA-MB-436 | Bleomycin | Radiation | Misc | 0.85488 | -0.1198 | 0.3092 | 0.0484 | 0.9195 | 1.4366 | 0.98079 |
MDA-MB-436 | Ipatasertib | AKT | PI3K/mTOR | 25.8679 | 0.6111 | 0.1038 | 0.0116 | 0.4073 | 383.9431 | 0.92516 |
MDA-MB-436 | Alpelisib | PI3Ka | PI3K/mTOR | 36.7582 | 0.7252 | 0.0552 | 0.0073 | 0.6026 | 226.7201 | 0.84658 |
MDA-MB-436 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 4.6563 | 0.2431 | 0.1736 | 0.0143 | 0.6355 | 26.2348 | 0.92245 |
MDA-MB-436 | TGX221 | PI3Kb | PI3K/mTOR | 22.0461 | 0.7221 | 0.0019 | 0.0048 | 1.3022 | 18.6589 | 0.84405 |
MDA-MB-436 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.041679 | 0.1227 | 0.3390 | 0.0305 | 0.6859 | 0.029409 | 0.97813 |
MDA-MB-436 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.6148 | 0.3144 | 0.0169 | 0.7543 | 0.00065027 | 0.85083 |
MDA-MB-436 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.024105 | 0.2111 | 0.4295 | 0.0250 | 1.0988 | 0.010706 | 0.97335 |
MDA-MB-436 | PF-4708671 | p70S6K | PI3K/mTOR | 4.7528 | 0.1938 | 0.0918 | 0.0048 | 1.3212 | 6.5976 | 0.98815 |
MDA-MB-436 | Buparlisib | pan PI3K | PI3K/mTOR | 1.1815 | -0.2866 | 0.2925 | 0.0578 | 1.6196 | 1.6556 | 0.99244 |
MDA-MB-436 | Pictilisib | pan PI3K | PI3K/mTOR | 5.2741 | 0.2850 | 0.1328 | 0.0124 | 0.7767 | 21.6999 | 0.98441 |
MDA-MB-436 | Ceritinib | ALK | RTK | 0.49893 | -0.6974 | 0.4169 | 0.1006 | 0.9667 | 1.4927 | 0.99602 |
MDA-MB-436 | Neratinib | EGFR/HER2 | RTK | 0.71562 | 0.0162 | 0.1879 | 0.0162 | 0.8626 | 1.6615 | 0.98931 |
MDA-MB-436 | Tivantinib | MET | RTK | 0.3675 | -0.2711 | 0.4215 | 0.0897 | 2.2220 | 0.44342 | 0.99833 |
MDA-MB-436 | Cediranib | VEGFR/cKIT | RTK | 3.6098 | -0.3824 | 0.1610 | 0.0446 | 1.8229 | 6.595 | 0.98039 |
MDA-MB-436 | Cabozantinib | VEGFR2/MET | RTK | 6.5187 | 0.0862 | 0.0592 | 0.0149 | 2.1788 | 10.7014 | 0.98785 |
MDA-MB-453 | Abemaciclib | CDK4/6 | Cell cycle | 0.0057723 | -0.7647 | 0.8495 | 0.1526 | 0.2725 | 0.32512 | 0.73985 |
MDA-MB-453 | Palbociclib | CDK4/6 | Cell cycle | 0.042838 | 0.0416 | 0.4402 | 0.0770 | 1.2886 | 0.039852 | 0.99219 |
MDA-MB-453 | AZD7762 | CHK1/2 | Cell cycle | 0.011509 | -0.2157 | 0.8564 | 0.1405 | 1.6714 | 0.014102 | 0.99393 |
MDA-MB-453 | Volasertib | PLK | Cell cycle | 0.0071952 | -0.2013 | 0.5350 | 0.1191 | 2.7557 | 0.0074665 | 0.98353 |
MDA-MB-453 | Dinaciclib | pan CDK | Cell cycle | 0.011359 | -0.2569 | 0.5807 | 0.1358 | 3.4728 | 0.012824 | 0.99835 |
MDA-MB-453 | Cisplatin | Chemo | Chemotherapy | 3.4106 | 0.1328 | 0.0938 | -0.0013 | 3.0256 | 3.151 | 0.9887 |